Meta-analysis of 49 studies of advanced therapies for extraintestinal manifestations of IBD: musculoskeletal response was 61% with TNF antagonists, 65% with JAK inhibitors and 42% with vedolizumab (12% axial); skin response 89–91% with TNF and anti-IL.
Meta-analysisn = 49 studies
Sachdeva et al. Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis